Streetbeat News

Revenues

MTN

Vail Resorts (NYSE:MTN) has received mixed analyst ratings over the past three months, with a shift towards a more bearish sentiment. The average 12-month price target was adjusted to $248.25, marking a 2.38% decrease. Analysts from firms like Stifel, Morgan Stanley, and JP Morgan have adjusted their price targets and ratings, reflecting concerns over Vail Resorts' financial performance, including a -7.47% revenue decline and challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 5:00 pm

KIM

Kimco Realty (NYSE:KIM) has been analyzed by 5 analysts in the last three months, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $22.2, with recent actions including both raises and lowers in ratings and price targets by analysts from Evercore ISI Group, Jefferies, Mizuho, and Piper Sandler. Kimco Realty, a significant player in the real estate investment trust sector, has shown a revenue growth of 2.68% as of December 31, 2023, but faces challenges in net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 5:00 pm

IR

In the last three months, 7 analysts have updated their ratings on Ingersoll Rand (NYSE:IR), showing a mix of bullish to indifferent sentiments. The average 12-month price target for IR has increased by 16.55% to $91.29. Analysts from firms like Goldman Sachs and Wells Fargo have raised their price targets, reflecting positive market dynamics and company performance. Ingersoll Rand, with a diverse portfolio in industrial and precision technologies, reported a revenue growth of 12.18% and a net margin of 12.62% for 2023, although its ROE and ROA are below industry averages.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 5:00 pm

OPRX

OptimizeRx shares are trading lower after the company reaffirmed its FY23 revenue guidance, indicating no upward revision to its financial outlook.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 4:59 pm

NFLX

Netflix Inc (NASDAQ:NFLX) is expected to continue its streaming dominance, with an analyst from Oppenheimer, Jason Helfstein, raising the price target from $615 to $725. Helfstein cites potential revenue and subscriber growth beyond Street estimates, driven by converting shared customers to paid plans, advertising growth on cheaper plans, and content advantages. Netflix ended Q4 with 260.28 million global paid subscribers and is anticipated to outperform with upcoming price increases in key markets and improved ad monetization.

Portfolio Pulse from Chris Katje

March 12, 2024 | 4:58 pm

DAL

LUV

Delta Air Lines, Inc. (NYSE:DAL) shares dropped after the company provided an update on its financial outlook, expecting to hit the top half of its initial revenue growth guidance for the March quarter. Despite this, Delta reiterated its FY24 earnings forecast and provided details on its adjusted debt to EBITDA ratio. Meanwhile, Southwest Airlines Co (NYSE:LUV) also adjusted its first-quarter guidance due to operational challenges, impacting its stock.

Portfolio Pulse from Nabaparna Bhattacharya

March 12, 2024 | 4:25 pm

INDV

Indivior PLC (NASDAQ:INDV) announced successful results from a pharmacodynamic study showing that its nasal spray, OPVEE, rapidly reverses opioid-induced respiratory depression, a major cause of death from opioid overdose, more effectively than naloxone. The study, part of the OPVEE development program, demonstrated OPVEE's superiority in reversing the effects of remifentanil, a synthetic opioid related to fentanyl, within the first 5 minutes of administration.

Portfolio Pulse from Jelena Martinovic

March 12, 2024 | 4:23 pm

BCAN

BLDE

CLRO

NRXP

PACK

RGLS

Nasdaq Composite gained around 1% amid positive U.S. stock market movements. ClearOne, Inc. announced a special cash dividend, causing shares to surge 120%. Regulus Therapeutics and Ranpak Holdings also saw significant gains following positive announcements. Conversely, BYND Cannasoft, Blade Air Mobility, and NRx Pharmaceuticals experienced sharp declines due to various negative developments. The U.S. consumer price index for February 2024 indicated higher-than-expected inflation rates.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 4:10 pm

INCY

In the past three months, 8 analysts have provided diverse ratings for Incyte (NASDAQ:INCY), with a mix of bullish and indifferent perspectives. The average 12-month price target is $73.12, slightly down from the previous $73.83. Analysts' actions include maintaining, raising, and lowering ratings and price targets, reflecting their response to Incyte's market performance and developments. Incyte's financial performance shows a revenue growth of 9.35% but below industry benchmarks in net margin, ROE, and ROA, indicating challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 4:00 pm

LTRX

In the last three months, 4 analysts have published ratings on Lantronix (LTRX), all bullish, with a decrease in the average 12-month price target from $9.67 to $7.88. The company has shown positive revenue growth and strong financial performance, with a notable increase in top-line earnings and surpassing industry standards in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 4:00 pm